<p>Merit Financial Group LLC 在最近向证券交易委员会的披露中表示，在第三季度将其在雅培（NYSE:ABT - 免费报告）股票的持有量提高了 32.7%。该公司在季度内购买了 20,035 股后，持有 81,264 股这家医疗产品制造商的股票。根据其最近的 SEC 文件，Merit Financial Group LLC 在雅培的持股价值为 10,884,000 美元。</p>
<p>获取 <strong>雅培</strong> 的提醒：</p>
<ul>
<li>博通刚刚提高了其股息——但这并不是唯一一个显示出强劲信号的公司</li>
</ul>
<p>其他几家机构投资者也对该股票的持仓进行了调整。IMG Wealth Management Inc.在第二季度将其在雅培的股份增加了 759.1%。IMG Wealth Management Inc.现在拥有 189 股这家医疗产品制造商的股票，价值 26,000 美元，此前在该期间又购买了 167 股。Anfield Capital Management LLC 在第二季度将其在雅培的持股增加了 81.3%。Anfield Capital Management LLC 现在拥有 232 股这家医疗产品制造商的股票，价值 32,000 美元，此前在上个季度又购买了 104 股。Delos Wealth Advisors LLC 在第二季度购买了雅培的新头寸，价值 32,000 美元。Curio Wealth LLC 在第二季度将其在雅培的股份提高了 15,250.0%。Curio Wealth LLC 现在拥有 307 股这家医疗产品制造商的股票，估值为 42,000 美元，此前在上个季度又购买了 305 股。最后，Pineridge Advisors LLC 在第二季度将其在雅培的持仓提高了 34.6%。Pineridge Advisors LLC 现在拥有 315 股这家医疗产品制造商的股票，价值 43,000 美元，此前在该期间又购买了 81 股。当前 75.18% 的股票由机构投资者持有。</p>
<h2>华尔街分析师观点</h2>
<p>ABT 已经成为几份分析师报告的主题。Jefferies Financial Group 在 10 月 16 日的研究报告中将雅培的目标股价从 145.00 美元提高至 149.00 美元，并给予该公司 “买入” 评级。BTIG Research 在 11 月 20 日的研究报告中重申了 “买入” 评级，并对雅培的股票设定了 145.00 美元的目标价。加拿大皇家银行在 10 月 16 日的研究报告中重申了 “跑赢大盘” 评级，并设定了 147.00 美元的目标价。Benchmark 在 10 月 10 日的报告中开始覆盖雅培。他们对该股票给予了 “买入” 评级，并设定了 145.00 美元的目标价。最后，富国银行在 10 月 16 日的报告中将雅培的目标价从 142.00 美元提高至 146.00 美元，并给予该股票 “超配” 评级。两位投资分析师对该股票给予了强烈买入评级，十七位给予了买入评级，四位给予了持有评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “适度买入”，平均目标价为 147.00 美元。</p>
<ul>
<li>ABBV 股票：250 美元可能是大 Q3 财报后新的底线</li>
</ul>
<p><strong>获取我们最新的 ABT 股票报告</strong></p>
<h2>雅培股票下跌 0.4%</h2>
<p>NYSE:ABT 的股票在周四开盘时为 125.30 美元。雅培的 52 周低点为 110.86 美元，52 周高点为 141.23 美元。该公司的市值为 2178.8 亿美元，市盈率为 15.70，市盈增长比率为 2.29，贝塔值为 0.72。该公司的债务股本比为 0.23，速动比率为 1.24，流动比率为 1.70。该公司的 50 日移动平均线为 126.06 美元，200 日移动平均线为 129.72 美元。</p>
<ul>
<li>雅培在十月的价格暴跌是买入的信号</li>
</ul>
<p>雅培（NYSE:ABT - 获取免费报告）在 10 月 15 日星期三发布了其季度财报。这家医疗产品制造商报告该季度每股收益为 1.30 美元，符合市场共识预期的 1.30 美元。雅培的股本回报率为 17.60%，净利润率为 31.88%。该公司在该季度的收入为 113.7 亿美元，而市场共识预期为 114 亿美元。去年同期，该公司每股收益为 1.21 美元。雅培该季度的收入同比增长 6.9%。雅培已将其 2025 财年的指引设定为每股收益 5.120-5.180 美元。分析师平均预测雅培在当前财年将发布每股收益 5.14 美元。</p>
<h2>雅培增加股息</h2>
<p>该公司最近还披露了一项季度股息，将于 2 月 13 日星期五支付。1 月 15 日星期四的股东将获得 0.63 美元的股息。这比雅培之前的季度股息 0.59 美元有所增加。这代表着每年 2.52 美元的股息和 2.0% 的股息收益率。该股息的除息日期为 1 月 15 日星期四。雅培的派息比率目前为 29.57%。</p>
<h2>雅培公司简介</h2>
<p>（免费报告）</p>
<p>雅培是一家全球医疗保健公司，总部位于伊利诺伊州的雅培公园，开发、制造和销售广泛的医疗产品和服务。雅培成立于 1888 年，通过多个业务领域运营，专注于诊断、医疗设备、营养品和成熟药品。该公司向医院、诊所、实验室、零售商和直接面向消费者的渠道提供旨在诊断、治疗和管理各种健康状况的产品。</p>
<p>在诊断方面，雅培提供实验室和现场检测平台及试剂，用于检测传染病、慢性疾病和生物标志物；其 Alinity 系列仪器和快速检测解决方案就是这一能力的例子。</p>
<h2>特色文章</h2>
<ul>
<li>我们更看好的五只股票，胜过雅培</li>
<li>这个假期你花 1 美元能买到的最佳商品</li>
<li>假期惊喜：1 美元让你拥有一切</li>
<li>美国 “最糟糕” 的圣诞促销</li>
<li>市场恐慌：特朗普刚刚对你的股票投下了一颗炸弹</li>
<li>你家族的财富在 2026 年到期？</li>
</ul>
<p><strong>想看看其他对雅培持有股份的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取雅培（NYSE:ABT - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在雅培吗？</h2>
<p>在考虑雅培之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而雅培并不在名单上。</p>
<p>虽然雅培目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

雅培

<p>Merit Financial Group LLC 在第三季度将其在雅培（NYSE:ABT）的持股增加了 32.7%，额外购买了 20,035 股，总持股达到 81,264 股，价值 1,088 万美元。其他机构投资者也显著增加了他们的持仓。分析师对雅培持乐观态度，普遍评级为 “适度买入”，平均目标价为 147.00 美元。雅培的股票开盘价为 125.30 美元，52 周区间为 110.86 美元至 141.23 美元。该公司报告第三季度每股收益为 1.30 美元，符合预期，并已将 2025 财年的指导目标设定为每股收益 5.120-5.180 美元</p>

<p>Merit Financial Group LLC lifted its holdings in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 32.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 81,264 shares of the healthcare product maker's stock after purchasing an additional 20,035 shares during the quarter. Merit Financial Group LLC's holdings in Abbott Laboratories were worth $10,884,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Merit Financial Group LLC 在最近向证券交易委员会的披露中表示，在第三季度将其在雅培（NYSE:ABT - 免费报告）股票的持有量提高了 32.7%。该公司在季度内购买了 20,035 股后，持有 81,264 股这家医疗产品制造商的股票。根据其最近的 SEC 文件，Merit Financial Group LLC 在雅培的持股价值为 10,884,000 美元。</p>
</div><p>Get <strong>Abbott Laboratories</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>雅培</strong> 的提醒：</p>
</div><ul>
<li>Broadcom Just Raised Its Dividend—But It’s Not the Only One Signaling Strength</li>
</ul>
<div class="lb-trans"><ul>
<li>博通刚刚提高了其股息——但这并不是唯一一个显示出强劲信号的公司</li>
</ul>
</div><p>Several other institutional investors have also made changes to their positions in the stock. IMG Wealth Management Inc. increased its stake in Abbott Laboratories by 759.1% during the 2nd quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker's stock worth $26,000 after acquiring an additional 167 shares during the period. Anfield Capital Management LLC grew its holdings in shares of Abbott Laboratories by 81.3% during the 2nd quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker's stock worth $32,000 after purchasing an additional 104 shares in the last quarter. Delos Wealth Advisors LLC bought a new position in shares of Abbott Laboratories in the second quarter worth $32,000. Curio Wealth LLC raised its stake in Abbott Laboratories by 15,250.0% in the second quarter. Curio Wealth LLC now owns 307 shares of the healthcare product maker's stock valued at $42,000 after purchasing an additional 305 shares in the last quarter. Finally, Pineridge Advisors LLC lifted its position in Abbott Laboratories by 34.6% during the second quarter. Pineridge Advisors LLC now owns 315 shares of the healthcare product maker's stock worth $43,000 after purchasing an additional 81 shares during the period. 75.18% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>其他几家机构投资者也对该股票的持仓进行了调整。IMG Wealth Management Inc.在第二季度将其在雅培的股份增加了 759.1%。IMG Wealth Management Inc.现在拥有 189 股这家医疗产品制造商的股票，价值 26,000 美元，此前在该期间又购买了 167 股。Anfield Capital Management LLC 在第二季度将其在雅培的持股增加了 81.3%。Anfield Capital Management LLC 现在拥有 232 股这家医疗产品制造商的股票，价值 32,000 美元，此前在上个季度又购买了 104 股。Delos Wealth Advisors LLC 在第二季度购买了雅培的新头寸，价值 32,000 美元。Curio Wealth LLC 在第二季度将其在雅培的股份提高了 15,250.0%。Curio Wealth LLC 现在拥有 307 股这家医疗产品制造商的股票，估值为 42,000 美元，此前在上个季度又购买了 305 股。最后，Pineridge Advisors LLC 在第二季度将其在雅培的持仓提高了 34.6%。Pineridge Advisors LLC 现在拥有 315 股这家医疗产品制造商的股票，价值 43,000 美元，此前在该期间又购买了 81 股。当前 75.18% 的股票由机构投资者持有。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>ABT has been the subject of several analyst reports. Jefferies Financial Group boosted their target price on shares of Abbott Laboratories from $145.00 to $149.00 and gave the company a &#34;buy&#34; rating in a research report on Thursday, October 16th. BTIG Research reissued a &#34;buy&#34; rating and issued a $145.00 price objective on shares of Abbott Laboratories in a research note on Thursday, November 20th. Royal Bank Of Canada restated an &#34;outperform&#34; rating and set a $147.00 target price on shares of Abbott Laboratories in a research note on Thursday, October 16th. Benchmark initiated coverage on Abbott Laboratories in a report on Friday, October 10th. They issued a &#34;buy&#34; rating and a $145.00 target price on the stock. Finally, Wells Fargo &amp; Company boosted their price target on Abbott Laboratories from $142.00 to $146.00 and gave the stock an &#34;overweight&#34; rating in a report on Thursday, October 16th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of &#34;Moderate Buy&#34; and an average price target of $147.00.</p>
<div class="lb-trans"><p>ABT 已经成为几份分析师报告的主题。Jefferies Financial Group 在 10 月 16 日的研究报告中将雅培的目标股价从 145.00 美元提高至 149.00 美元，并给予该公司 “买入” 评级。BTIG Research 在 11 月 20 日的研究报告中重申了 “买入” 评级，并对雅培的股票设定了 145.00 美元的目标价。加拿大皇家银行在 10 月 16 日的研究报告中重申了 “跑赢大盘” 评级，并设定了 147.00 美元的目标价。Benchmark 在 10 月 10 日的报告中开始覆盖雅培。他们对该股票给予了 “买入” 评级，并设定了 145.00 美元的目标价。最后，富国银行在 10 月 16 日的报告中将雅培的目标价从 142.00 美元提高至 146.00 美元，并给予该股票 “超配” 评级。两位投资分析师对该股票给予了强烈买入评级，十七位给予了买入评级，四位给予了持有评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “适度买入”，平均目标价为 147.00 美元。</p>
</div><ul>
<li>ABBV Stock: $250 May Be the New Floor After Big Q3 Earnings Beat</li>
</ul>
<div class="lb-trans"><ul>
<li>ABBV 股票：250 美元可能是大 Q3 财报后新的底线</li>
</ul>
</div><p><strong>Get Our Latest Stock Report on ABT</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 ABT 股票报告</strong></p>
</div><h2>Abbott Laboratories Stock Down 0.4%</h2>
<div class="lb-trans"><h2>雅培股票下跌 0.4%</h2>
</div><p>Shares of NYSE:ABT opened at $125.30 on Thursday. Abbott Laboratories has a 52-week low of $110.86 and a 52-week high of $141.23. The company has a market capitalization of $217.88 billion, a PE ratio of 15.70, a price-to-earnings-growth ratio of 2.29 and a beta of 0.72. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.24 and a current ratio of 1.70. The company has a fifty day moving average of $126.06 and a 200-day moving average of $129.72.</p>
<div class="lb-trans"><p>NYSE:ABT 的股票在周四开盘时为 125.30 美元。雅培的 52 周低点为 110.86 美元，52 周高点为 141.23 美元。该公司的市值为 2178.8 亿美元，市盈率为 15.70，市盈增长比率为 2.29，贝塔值为 0.72。该公司的债务股本比为 0.23，速动比率为 1.24，流动比率为 1.70。该公司的 50 日移动平均线为 126.06 美元，200 日移动平均线为 129.72 美元。</p>
</div><ul>
<li>Abbott Laboratories' October Price Plunge Is a Signal to Buy</li>
</ul>
<div class="lb-trans"><ul>
<li>雅培在十月的价格暴跌是买入的信号</li>
</ul>
</div><p>Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings data on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share for the quarter, meeting the consensus estimate of $1.30. Abbott Laboratories had a return on equity of 17.60% and a net margin of 31.88%.The company had revenue of $11.37 billion for the quarter, compared to the consensus estimate of $11.40 billion. During the same quarter last year, the business posted $1.21 EPS. Abbott Laboratories's revenue for the quarter was up 6.9% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. On average, equities analysts predict that Abbott Laboratories will post 5.14 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>雅培（NYSE:ABT - 获取免费报告）在 10 月 15 日星期三发布了其季度财报。这家医疗产品制造商报告该季度每股收益为 1.30 美元，符合市场共识预期的 1.30 美元。雅培的股本回报率为 17.60%，净利润率为 31.88%。该公司在该季度的收入为 113.7 亿美元，而市场共识预期为 114 亿美元。去年同期，该公司每股收益为 1.21 美元。雅培该季度的收入同比增长 6.9%。雅培已将其 2025 财年的指引设定为每股收益 5.120-5.180 美元。分析师平均预测雅培在当前财年将发布每股收益 5.14 美元。</p>
</div><h2>Abbott Laboratories Increases Dividend</h2>
<div class="lb-trans"><h2>雅培增加股息</h2>
</div><p>The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 13th. Stockholders of record on Thursday, January 15th will be paid a $0.63 dividend. This is an increase from Abbott Laboratories's previous quarterly dividend of $0.59. This represents a $2.52 annualized dividend and a dividend yield of 2.0%. The ex-dividend date of this dividend is Thursday, January 15th. Abbott Laboratories's payout ratio is currently 29.57%.</p>
<div class="lb-trans"><p>该公司最近还披露了一项季度股息，将于 2 月 13 日星期五支付。1 月 15 日星期四的股东将获得 0.63 美元的股息。这比雅培之前的季度股息 0.59 美元有所增加。这代表着每年 2.52 美元的股息和 2.0% 的股息收益率。该股息的除息日期为 1 月 15 日星期四。雅培的派息比率目前为 29.57%。</p>
</div><h2>Abbott Laboratories Profile</h2>
<div class="lb-trans"><h2>雅培公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.</p>
<div class="lb-trans"><p>雅培是一家全球医疗保健公司，总部位于伊利诺伊州的雅培公园，开发、制造和销售广泛的医疗产品和服务。雅培成立于 1888 年，通过多个业务领域运营，专注于诊断、医疗设备、营养品和成熟药品。该公司向医院、诊所、实验室、零售商和直接面向消费者的渠道提供旨在诊断、治疗和管理各种健康状况的产品。</p>
</div><p>In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.</p>
<div class="lb-trans"><p>在诊断方面，雅培提供实验室和现场检测平台及试剂，用于检测传染病、慢性疾病和生物标志物；其 Alinity 系列仪器和快速检测解决方案就是这一能力的例子。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than Abbott Laboratories</li>
<li>The Best $1 You'll Spend This Holiday Season</li>
<li>Holiday surprise: $1 gets you everything</li>
<li>America’s “most deplorable” Christmas sale</li>
<li>Market Panic: Trump Just Dropped a Bomb on Your Stocks</li>
<li>Your family's wealth expires in 2026?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过雅培</li>
<li>这个假期你花 1 美元能买到的最佳商品</li>
<li>假期惊喜：1 美元让你拥有一切</li>
<li>美国 “最糟糕” 的圣诞促销</li>
<li>市场恐慌：特朗普刚刚对你的股票投下了一颗炸弹</li>
<li>你家族的财富在 2026 年到期？</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding ABT?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对雅培持有股份的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取雅培（NYSE:ABT - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=ABT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Abbott Laboratories Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在雅培吗？</h2>
</div><p>Before you consider Abbott Laboratories, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑雅培之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而雅培并不在名单上。</p>
</div><p>While Abbott Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然雅培目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Merit Financial Group LLC 收购了雅培实验室 20,035 股股票 $ABT